作者: G.C. Sotiropoulos , K.W. Nowak , I. Fouzas , S. Vernadakis , S. Kykalos
DOI: 10.1016/J.TRANSPROCEED.2012.09.022
关键词:
摘要: Abstract Background With an increasing number of patients with hepatocellular carcinoma (HCC) undergoing liver transplantation (OLT), HCC recurrence remains the main limiting factor for long-term survival. We herein report our experience sorafenib treatment post-OLT. Patients and Methods reviewed data on transplanted receiving recurrence. Results Fourteen were included period November 2006 to February 2011. There 9 men 5 women median age 57 years. Twelve (86%) received rescue grafts through Eurotransplant allocation. Median values alpha fetoprotein levels, Model End-Stage Liver Disease score, daily dose, length 97 ng/mL, 10, 400 mg, 6.5 months, respectively. Sorafenib side effects led discontinuation ( n = 4) or reduction 2) dose. Four experienced tumor progression during treatment. Seven are currently alive, 3 died progression, 4 non–tumor-related causes death. survival was 25 months. Conclusion in transplant recipients represents a challenging oncologic approach that requires further validation prospective, multicenter studies.